狂犬病暴露后预防处置进展

张董 冯子健

张董, 冯子健. 狂犬病暴露后预防处置进展[J]. 疾病监测, 2008, 23(2): 121-125. doi: 10.3784/j.issn.1003-9961.2008.2.121
引用本文: 张董, 冯子健. 狂犬病暴露后预防处置进展[J]. 疾病监测, 2008, 23(2): 121-125. doi: 10.3784/j.issn.1003-9961.2008.2.121
ZHANG Dong, FENG Zi-jian . Advances in rabies post-exposure prophylaxis[J]. Disease Surveillance, 2008, 23(2): 121-125. doi: 10.3784/j.issn.1003-9961.2008.2.121
Citation: ZHANG Dong, FENG Zi-jian . Advances in rabies post-exposure prophylaxis[J]. Disease Surveillance, 2008, 23(2): 121-125. doi: 10.3784/j.issn.1003-9961.2008.2.121

狂犬病暴露后预防处置进展

doi: 10.3784/j.issn.1003-9961.2008.2.121

Advances in rabies post-exposure prophylaxis

  • 摘要: 本文介绍了WHO推荐的狂犬病暴露后预防处置三方面的进展,主要包括狂犬病疫苗的种类、免疫程序、被动免疫制剂的国内外发展和使用情况,论述了其效果以及在中国应用的可能性,并初步探讨如何促进中国的狂犬病暴露后预防处置.
  • [1]Xiong CL,Zhang YZ,Lu SQ,et al.Advances in the study of biological characteristics of rabies virus[J].Chinese J Epidemiol,2006,27(10):913.(in Chinses)熊成龙,张永振,卢思奇,等.狂犬病病毒生物学特征研究进展[J].中华流行病学杂志,2006,27(10):913. [2]WHO Expert consultation on rabies,5-8 October 2004.Technical report series 931 first report.Accessed at http://www.who.int/rabies/931/en/index.html. [3]Tang JQ.Natural focus diseases[M].Beijing:Science Press,2005:358-392.(in Chinese)唐家琪.自然疫源性疾病[M].北京:科学出版社,2005:358-392. [4]Yusibov V,Hooper DC,Spitsin sv,et al.Expression in plants and immunogenicity of plant vires based experimental rabies[J].Vaccine,2002,20(25-26):3155-3164. [5]Lin HX,Perrin P.The effect of aluminum adjuvants on experimental rabies vaccine[J].Chinese J Exp Clini Virol,1999,2(13):133-135.(in Chinese)林海祥,Perrin P.铝佐剂对实验狂犬病疫苗的影响[J].中华实验和临床病毒学杂志,1999,2(13):133-135. [6]Yan JX,Li CP,Zhu JH,et al Establishment of the rapid fluorescent focus inhibition test(RFFIT) for the detection of the antibodies to rabiesvirus[J].Chinese J Biol,1998,11(2):93-96.(in Chinese)严家新,李承平,朱家鸿,等.检测狂犬病毒中和抗体的快速荧光灶抑制试验(RFFIT)方法的建立[J].中国生物制品学杂志,1998,11(2):93-96. [7]Lodmell DL,Ray NB,Ulrich JT,et al.DNA vaccination of mice against rabies virus:effects of the route of vaccination and the adjuvant monophosphoryl lipid A(MPL)[J].Vaccine,2000,18(11-12):1059-1066. [8]Guo XX,Yang Q,Liu Y,et al Immune effect of rabies virus liposome vaccine for human use[J].Chinese J Biol,2007,20(2):107-109.(in Chinese)郭秀侠,杨倩,刘岩,等.人用狂犬病脂质体疫苗的免疫效果[J].中国生物制品学杂志,2007,20(2):107-109. [9]Castignolles N,Morgeaux S,Gontier-Jallet C,et al.A new family of carriers (biovectors) enhances the immunogenicity of rabiesantigens[J].Vaccine,1996,14(14):1353-1360. [10]Cui YG,Wu XJ,Guo Y,et al.The effect of astragalus polysacharin(APS) on the immunogenicity of rabies vaccine for human use[J].Chinese J Biol 2006,19(5):492-496.(in Chinese)崔颖杰,吴晓娟,郭岩,等.黄芪多糖对人用狂犬病疫苗免疫原性的影响[J].中国生物制品学杂志,2006,19(5):492-496. [11]Zou Y,Song JP,Lv HI,et al.Immunogenicity and curative effect of rabies vaccine-interferon combined preparation[J].Chinese J Biol,2002,15(5):287-289.(in Chinese)邹勇,宋继萍,吕宏亮,等.狂犬病-干扰素联合制剂的免疫原性及治疗作用[J].中国生物制品学杂志,2002,15(5):287-289. [12]Leroy M,Pine G,Baise E,et al.Expression of the interferon-alpha/beta indueible bevine Mxl dynamin interferes with replication of rabies virus[J].Neurobiol Dis,2006,21(3):515-521. [13]Chávez JH,teal PC,Yunes RA,et al.Evaluation of antiviralactivity of phenohc compounds and derivatives against rabies virus[J].Vet Microbiol,2006,116(1-3):53-59. [14]Chavanet P,Sureau P,Waldner-Combernoux A,et al.A simplified method of vaccination against rabies after exposure[J].Presse Med,1989,18(16):813-815. [15]Chutivongse S,Wilde H,Fishbein DB,et al.One-year study of the 2-1-1 intramuscular pest exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and vero cell rabies vaccine[J].Vaccine,1991,9(8):573-576. [16]Gao GX,Li CZ,Wu TC,et al.Observation of the immune effects of rabies vaccine in different immunization schedules and injection methods[J].Gnansxi J Prey Med,2001,7(4):234-235.(inChinese)高贵霞,李冲之,吴泰才,等.狂犬疫苗不同免疫程序和注射方法的免疫效果观察[J].广西预防医学,2001,7(4):234-235. [17]Khawplod P,Wilde H,Sirkwin S,et al.Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection[J].Vaccine,2006,24(16):3084-3086. [18]Madhusadana SN,Anand NP,Shamsundar R.Evaluation of twointradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies[J].Natl Med J India,2001,14(3):145-147. [19]Ambrozaitis A,Laiskonis A,Balciuniene L,et al.Rabies post-ex-posure prophylaxis vaccination with purified chick embryo cellvaccine (PCECV) and purified vero cell rabies vaccine (PVRV)in a four-site intradermal schedule (4-0-2-0-1-1):An immunogenie,cost-effective and practical regimen[J].Vaccine,2006,24(19):4116-4121. [20]Sudarshan MK,Madhusudana SN,Mahendra BJ,et al.Boostingeffect of purified chick embryo cell rabies vaccine using the intradermal route in persons previously immunized by the intramuscular route or vice versa[J].Natl Med J ladis,2006,19(4):192-194. [21]Intradermal application of rabies vaccines.Report of a WHO consultation.Bangkok,Thailand 5-6 June 2000.Accessed at http://www.who.int/entity/rabies/en/Report_WHO_consultation_on_intradermal_application_of_human_rabies_vaccines.pdf. [22]Chhabra M,Ichhpujani RL,Bhardwaj M,et al.Safety and immunogenicity of the intradernud Thai Red Cross(2-2-2-0-1-1)postexposure vaccination rogimen in the Indian population using Purified chick embryo cell rabies vaccine[J].Indian J Med Microbiol,2005,23(1):24-28. [23]Lang J,Attanath P,Quiambao B,et al.Evaluation of the safety,immunogenicity,and pharmacokinetic profile of a new,highly purified,heat-treated equine rabies immunoglobulin,administered either alone or in association with a purified,Vero-cell rabies vaccine[J].Aeta Trop,1998,(70):317-333. [24]Schumacher CL Dietzschold B,Ertl HC,et al.Use of mouse antirabies monoclonal antibodies in post exposure treatment of rabies[J].J Clin Invest,1989,84(3):971-975. [25]Goudsmit J,Marissen WE,Weldon WC,et al.Comparison of antirabies human monoclonal antibody combination with human palyelonal anti-rabies immune globulin[J].Infec Dis,2006,193(6):796-801. [26]Sloan SE,Hanlon C,Weldon W,et al.Identification and charactefization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolares[J].Vaccine,2007,25(15):2800-2810. [27]Khawplod P,wilde H,Tepsumethanon S et al.Prospective Immunogenicity Study of Multiple Intradermal Injections of Rabies Vaccine in an Effort to Obrain an Early Immune Response without the Use of Immunoglobulin[J].Clin Infec Dis,2002,35(12):1562-1565. [28]Belotto A,Leanes LF,Schneider MC,et al.Overview of rabies in the Americas[J].Virus Res,2005(111):5-12. [29]Middaugh J,Bitter D.A comprehensive rabies control program in Alaska[J].AM J Public Health,1982,72(4):384-386. [30]Wan GR,Zhang L.Implementation of the rabies immune provention notification scheine and observations of its effects[J].Modern Prey Med,2007,34(10):1970.万桂荣,张林.狂犬病免疫预防告知制的实施及效果观察[J].现代预防医学,2007,34(10):1970.
  • 加载中
计量
  • 文章访问数:  1301
  • HTML全文浏览量:  52
  • PDF下载量:  615
  • 被引次数: 0
出版历程
  • 收稿日期:  2007-09-25
  • 刊出日期:  2008-02-29

目录

    /

    返回文章
    返回

    在线交流

    防诈骗公告

    近期有不法分子以本刊编辑身份添加作者微信,请务必提高警惕!本刊关于稿件的一切事项通知均采用编辑部唯一邮箱(jbjc@icdc.cn)和座机(010-58900732)联系作者,且在录用稿件后仅收取版面费,无其他任何名目费用(如审稿费和加急费等),非编辑部邮箱发送的本刊收费用通知等均为诈骗,不要随意汇入款项!如有可疑及时致电编辑部核实确认!